Using digital technology to manage chemotherapy-related nausea and vomiting in older adults
Official title: Serious Gaming for Chemotherapy-induced Nausea and Vomiting in Older Adults With Cancer: A Randomized Clinical Trial
Run by University of Central Florida · NCT05838638 · Data updated 2026-11-12
This study is testing a digital program to help older adults manage nausea and vomiting while they go through chemotherapy to see if it improves their quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 60 Years and up |
| Sex | All |
| Enrollment | 610 (estimated) |
| Sponsor | University of Central Florida Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Miami, Florida and 1 other locations) |
| Status | Recruiting |
| Started | June 9, 2023 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT05838638 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 60 or older who are newly diagnosed with cancer and undergoing chemotherapy with moderate to high emetic potential.
✕Probably not a fit
Patients with a previous cancer diagnosis or those with end-stage disease are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study examines the effectiveness of a technology-based intervention aimed at managing nausea and vomiting in older adults undergoing chemotherapy. Participants will be randomly assigned to either an intervention group, which will receive the eSSET-CINV program, or a control group. The study will assess outcomes such as symptom severity, quality of life, and healthcare resource utilization over the course of 6 chemotherapy cycles, which may last between 12 to 24 weeks. The goal is to enhance self-management behaviors to reduce negative health outcomes and hospital admissions related to chemotherapy side effects.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the quality of life for older cancer patients by effectively managing chemotherapy-induced nausea and vomiting.
How similar studies have gone: Other studies have shown promise in using technology-based interventions for symptom management in cancer patients, suggesting a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 60 or older * newly diagnosed with cancer * treatment with any chemotherapeutic agent of moderate or high emetic potential * on a 2, 3 or 4 week treatment cycle * proficient in English * has a telephone Exclusion Criteria: * previous diagnosis and/or treatment for cancer * end stage disease with less than 6 months to live * visually or hearing impaired without corrective device
Where it's running
-
Miller School of Medicine Sylvester Comp. Cancer Center
Miami, Florida, United States Recruiting -
Orlando Health
Orlando, Florida, United States Recruiting
Study contacts
- Principal investigator: Victoria Loerzel, PhD — University of Central Florida
- Study coordinator: Victoria Loerzel, PhD
- Email: victoria.loerzel@ucf.edu
- Phone: 407-823-0762
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients
The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
Metastatic liver cancer patient registry from multiple Chinese centers
This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.
-
TriAdeno and N-803 vaccine in early prostate cancer on active surveillance
A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.